Market Trends of Europe Breast Cancer Screening Tests Industry
Mammograms Expected to Hold a Major Share in the Europe Breast Cancer Screening Test Market Over The Forecast Period
Mammograms are the most widely used tests to screen for breast cancer. Mammography is considered the gold standard technique used to screen breast cancer.
Governments and other healthcare organizations in the Europe region are taking initiatives to provide women, between the ages of 50 and 75, access to mammography screening, this is increasing the demand for mammography while laboratory and blood tests and other imaging tests are gaining popularity. For instance, as per the data from Eurostat published in October 2021, two-thirds (66%) of women aged between 50 and 69 years in the European Union reported that they had received a mammogram within the previous two years. Additionally, in September 2022, as a part of the European cancer screening scheme, the new EU approach is likely to support Member States ensuring that 90% of the EU population who qualify for breast cancer screenings are offered such screening by 2025. These initiatives to provide breast cancer screening is expected to propel the demand for mammograms in the region during the forecast period.
Furthermore, according to clinicaltrials.gov, a clinical trial was initiated in April 2021 to evaluate mammography screening with artificial intelligence (MASAI). The expected completion date of the trials is April 2025 and is sponsored by the regional council of Scania County in Sweden. The Cancer Registry of Norway also collaborated in the trial. The objective of this randomized controlled trial was to assess whether AI can improve the efficacy of mammography screening, compared with conventional mammography screening. The rising clinical trials of mammograms in the region are expected to create an opportunity for the market players for integrating advanced technologies such as AI in mammograms for more effective breast cancer screening.
Additionally, the launches by market players are also expected to accelerate the segment's growth. For instance, in November 2022, Hologic, Inc's 3Dimensions mammography system was awarded EUREF Type Test certification by the European Reference Organisation for Quality Assured Breast Screening and Diagnostic Services. It is one of the first digital breast tomosynthesis (DBT) systems to be certified, as well as one of only nine mammography systems in total. The launch of technologically advanced products is expected to boost the demand for mammograms and augment the segment's growth during the forecast period.
Therefore, owing to the above-mentioned factors such as rising government initiatives to boost breast screening, along with increasing clinical trials for the technological advancements in mammograms and launches is expected to witness significant growth in the segment during the forecast period.
Germany is Expected to Hold a Significant Share in the Europe Breast Cancer Screening Tests Market Over the Forecast Period
Germany is expected to hold a significant market share due to factors such as the high burden of breast cancer and rising awareness initiatives.
For instance, in February 2022, German startup Vara democratized access to breast cancer screening. The startup aims to provide every woman with lifesaving access to enhance breast cancer screening and recruited breast radiologists to fulfill the goal. Also, in October 2022, Berlin-based startup Vara raised USD 4.8 million (EUR 4.5 million) as it scaled its mission to make data-driven breast cancer screening accessible to everyone, everywhere.
Additionally, awareness campaigns in the country are expected to accelerate market growth during the forecast period. For instance, in October 2021, a breast cancer awareness campaign, 'Breast Cancer Affects Us All', was conducted by Wefra Life and the non-profit association Pink Ribbon Germany, to raise awareness about breast cancer, creating a sense of community around the issue, and promoting breast care, a free multilingual app that covers all relevant aspects of early breast cancer detection and prevention in the multimedia form in seven different languages. Such awareness initiatives are expected to increase the utility of breast cancer screening in the country thereby augmenting the market growth during the forecast period.
The rising launches by market players are projected to increase the market growth in the country. For instance, in April 2021, the Amulet Innovalitymammography system's new "Harmony" version was released by FUJIFILM Europe GmbH. The Amulet Innovalitymammography system from Fujifilm was available in the "Harmony" version, version AWS V9.3.
Therefore, owing to the factors such as the rising launches of screening tests by market players and increasing awareness initiatives in the country, the country is expected to witness growth during the forecast period.
